Not yet and not for another 2 quarters I'd say. Following their agreement, Linnea is assisting Bod in the development of the cannabis-based topical treatments for inflammation and sensitive skin, including serums, foam-based creams and balms. In November's announcement Bod was already conducting research and development in to its cannabis-based skincare products and was planning to begin commercialising and distributing the products to consumers during 2018. They announced that the products will be developed and manufactured at facilities in Italy, and exported to numerous major markets beyond Australia, including Asia and Americas.
A diversified and attractive product's pipeline but don't take my comments for advice and wait till the quarterly comes out, that'll help you see its value more clearly.
- Forums
- ASX - By Stock
- BOD
- Ann: Update on Fast Track of Phase I Clinical Trials
Ann: Update on Fast Track of Phase I Clinical Trials, page-10
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable